Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Inclusion Criteria All subjects * males or females aged 18 to 70 years inclusive (subjects with normal renal function, mild or moderate renal impairment), and 18 to 75 years inclusive (subjects with severe renal impairment) * body mass index 18.0 to 40.0 kilogram (kg)/square meter (m\^2) inclusive * females who are non-pregnant, non-lactating, or postmenopausal for \>=1 year, surgically sterile for \>= 90 days, or agree to use approved methods of contraception * males will be sterile or use approved methods of contraception * understands and signs informed consent form Healthy subjects with normal renal function * negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in * good health with no clinically significant medical history, physical examination, vital signs, or 12-lead ECG * clinical laboratory tests within the reference range or not clinically significant * normal renal function (estimated CLcr \>90 mL/min) at Screening Subjects with mild, moderate or severe renal impairment * negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in or verification of a prescription for a positive test * renal impairment (estimated CLcr \<90 mL/min) * evidence of stable renal impairment defined as two separate estimated CLcr values within 25% * clinical laboratory results consistent with their renal condition or of no clinical significance for the study * abnormal laboratory values must not be clinically significant. Anemia secondary to renal disease is acceptable if hemoglobin is ≥9 g/dL and no clinically significant symptoms. Liver enzymes and bilirubin must be below twice the upper normal level * subjects with renal impairment must have stable underlying medical conditions \< 90 days before study start * stable medication regimen(s) (no new drug(s) or changed dosage(s) \<30 days before study drug) * in good general health, allowing for concurrent illnesses associated with chronic kidney disease Exclusion Criteria: All subjects: * history of hypersensitivity or allergies to any drug, unless approved by the Investigator and reviewed by Sponsor/Medical Monitor * participation in a study with receipt of an investigational drug \< 5 half-lives or 30 days (whichever is longer) before Check-in * use of alcohol, grapefruit, or caffeine-containing foods or beverages \< 72 hours before Check-in, unless approved by the Investigator and reviewed by the Sponsor/Medical Monitor * poor peripheral venous access * whole blood donation \< 56 days before dosing or plasma donation \< 14 days before dosing * receipt of blood products \< 2 months before Check-in * history or presence of any clinically significant abnormal ECG * history of alcoholism or drug addiction \< 1 year before Check-in * positive test for HIV antibody, HBsAg or anti-HCV * pregnant or breastfeeding Healthy subjects with normal renal function: * use of any tobacco- or nicotine-containing products \< 6 months before Check-in * clinically significant (history of or active) cardiac, hepatic, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease putting the subject at increased risk or could interfere with study objectives * screening laboratory values outside normal range and deemed clinically significant by the Investigator * use of a prescription drug \< 14 days of dosing or a non-prescription drug \< 7 days before dosing or need of concomitant medication during the study Subjects with mild, moderate, or severe renal impairment: * unstable disease (concurrent medical conditions that have changed significantly \< 90 days) * changes in concomitant prescription medications \< 30 days before dosing or expected changes during study * use of new non-prescription medication \< 30 days before dosing * renal transplant * acute or chronic non-renal condition limiting the subject's ability to complete and/or participate in the study